Oregon Cancer Institute Research Groups:Cell 616

From OpenWetWare

(Difference between revisions)
Jump to: navigation, search
Current revision (12:34, 22 March 2012) (view source)
 
(5 intermediate revisions not shown.)
Line 1: Line 1:
 +
{{Template:OHSU Knight Cancer Institute Research Groups}}
 +
 +
 +
==CELL/CANB 616 Syllabus==
{| border="1" cellpadding="2" cellspacing="0" style="border:#c9c9c9 1px solid; margin: 1em 1em 1em 0; border-collapse: collapse; width:900px" <!-- This line here formats your table for you.  Change the code to change the formatting of your table.-->
{| border="1" cellpadding="2" cellspacing="0" style="border:#c9c9c9 1px solid; margin: 1em 1em 1em 0; border-collapse: collapse; width:900px" <!-- This line here formats your table for you.  Change the code to change the formatting of your table.-->
| align="left" style="background:#f0f0f0;"|'''Week'''
| align="left" style="background:#f0f0f0;"|'''Week'''
Line 10: Line 14:
|1
|1
|M
|M
-
|March 28
+
|April 2
|Mutagenic Mechanisms
|Mutagenic Mechanisms
-
|Jon Oyer
+
|Mitch Turker
|
|
|--
|--
|
|
|W  
|W  
-
|March 30
+
|April 4
|Chemical Carcinogenesis/DNA Repair
|Chemical Carcinogenesis/DNA Repair
|Stephen Lloyd
|Stephen Lloyd
Line 24: Line 28:
|
|
|Th
|Th
-
|March 31
+
|April 5
-
|Autophagy, Apoptosis
+
|Cancer Stem Cells
-
|Mushui Dai
+
|Missy Wong
|
|
|--
|--
|2
|2
|M
|M
-
|April 4
+
|April 9
-
|Cancer Stem Cells
+
|Tumor Microenvironment
-
|Missy Wong
+
|Lisa Coussens
|
|
|--
|--
|
|
|W
|W
-
|April 6
+
|April 11
|Metastasis & Angiogenesis
|Metastasis & Angiogenesis
|Rosalie Sears
|Rosalie Sears
Line 44: Line 48:
|--
|--
|
|
 +
|TH
 +
|April 12
 +
|Imagining in Cancer
 +
|Charles Springer
|
|
 +
|--
 +
|3
 +
|M
 +
|April 16
 +
|Mutational Analysis of Solid Tumors - Sequenome
 +
|Chris Coreless
|
|
 +
|--
|
|
 +
|W
 +
|April 18
 +
|Predictive Gene Signatures
 +
|Paul Spellman
 +
|
 +
|--
 +
|
 +
|Th
 +
|April 19
 +
|Solid Cancer Path
 +
|Megan Troxel
 +
|
 +
|--
 +
|4
 +
|M
 +
|April 23
 +
|Targeted Cancer Therapies
 +
|Charles Lopez
 +
|
 +
|--
 +
|
 +
|W
 +
|April 25
 +
|Immunotherapy
 +
|Bernie Fox
 +
|
 +
|--
 +
|
 +
|Th
 +
|April 26
 +
|Novel Mech. of Drug Delivery
 +
|Wassana Yantasee
 +
|
 +
|--
 +
|5
 +
|M
 +
|April 30
 +
|Lung
 +
|Alan Sadler
 +
|
 +
|--
 +
|
 +
|W
 +
|May 2
 +
|Radiation Oncology
 +
|Charles Thomas
 +
|
 +
|--
 +
|
 +
|Th
 +
|May 3
 +
|Kidney
 +
|George Thomas
 +
|
 +
|--
 +
|6
 +
|M
 +
|May 7
 +
|Head and Neck
 +
|Neil Gross
 +
|NOTE TIME AND ROOM: 10am RJH 5524
 +
|--
 +
|
 +
|W
 +
|May 9
 +
|Breast
 +
|Steve Chui
 +
|NOTE TIME AND ROOM: 10am RJH 5524
 +
|--
 +
|
 +
|Th
 +
|May 10
 +
|RESEARCH WEEK
 +
|No class
 +
|
 +
|--
 +
|7
 +
|M
 +
|May 14
 +
|Ovarian
 +
|Tanja Pejovic
 +
|
 +
|--
 +
|
 +
|W
 +
|May 16
 +
|Prostate
 +
|Joshi Alumkal
 +
|
 +
|--
 +
|
 +
|Th
 +
|May 17
 +
|Skin
 +
|Justin Leitenberger
 +
|
 +
|--
 +
|8
 +
|M
 +
|May 21
 +
|GI
 +
|Charles Lopez
 +
|
 +
|--
 +
|
 +
|W
 +
|May 23
 +
|Pancreas
 +
|Gina Vacarro
 +
|
 +
|--
 +
|
 +
|Th
 +
|May 24
 +
|Clinical Hem. Malignancy
 +
|W. Harv. Fleming
 +
|
 +
|--
 +
|9
 +
|M
 +
|May 28
 +
|MEMORIAL DAY
 +
|No Class
 +
|
 +
|--
 +
|
 +
|W
 +
|May 30
 +
|Basic Science Hem Malignancy
 +
|Jeff Tyner
 +
|
 +
|--
 +
|
 +
|Th
 +
|May 31
 +
|Nutrition and Cancer
 +
|Jackie Shannon
 +
|
 +
|--
 +
|10
 +
|M
 +
|June 4
 +
|Liver
 +
|Scott Naugler
 +
|
 +
|--
 +
|
 +
|W
 +
|June 6
 +
|Brain Cancer - Adult
 +
|Edward Neuwelt
 +
|
 +
|--
 +
|
 +
|Th
 +
|June 7
 +
|Tumor Board I
 +
|Sears/Wong
 +
|
 +
|--
 +
|11
 +
|M
 +
|June 11
 +
|Brain Cancer - pediatric
 +
|Kellie Nazemi
 +
|
 +
|--
 +
|
 +
|W
 +
|June 13
 +
|Tumor Board II
 +
|Sears/Wong
 +
|
 +
|--
 +
|
 +
|Th
 +
|June 14
 +
|Pediatric Cancers
 +
|Charles Keller
|
|
|}
|}
 +
 +
CELL616/CANB616 Advanced Topics in Cancer Biology Expectations
 +
Spring 2012
 +
 +
Goals of the course
 +
This upper level course will provide clinical insight into the clinical course, pathology, treatment, and therapeutic challenges that exist in a number of different organ-specific cancers. These clinical hallmarks and challenges are the important foundation on which novel basic science cancer research is built.
 +
 +
The course is designed to explore cancer mechanisms, hallmarks and novel technical approaches to unraveling underlying cancer behavior and characteristics, as well as organ-specific challenges, including current state of clinical diagnoses, treatment, prognosis and development of novel therapies. These lectures are designed to address the state of the art and to provide insight into the future of the field.
 +
 +
A critical aspect of the course is to provide the opportunity to basic science researchers to interact with clinical faculty. This will be accomplished through in class lectures, attendance at tumor-board, and shadowing with a clinical oncologist. We believe that this experience provides the opportunity to begin to understand the clinical challenges that can ultimately guide important discoveries in basic cancer research.
 +
 +
 +
Grading policy
 +
 +
Your grade will be based upon three criteria:
 +
 +
1. Class participation (30%)
 +
How interactive you are during the lecture
 +
 +
2. Your tumor board presentation (30%)
 +
 +
3. Final Exam (40%)
 +
This exam is a written 2 page review of one cancer type (your choice).
 +
 +
Within this review you will include information addressing: background on this type of cancer, demographics, current therapies, known molecular mechanisms, molecular and animal models that exist, cutting edge research being performed to elucidate the underlying molecular pathway and/or development of novel therapeutics.

Current revision

Equipped with his five senses, man explores the universe around him and calls the adventure Science.  ~Edwin Powell Hubble, The Nature of Science, 1954

Home        Faculty        Graduate Program        Postdocs        OHSU Knight Core Facilities       



Programs     Res Group Meetings        Cancer Journal Club        Cell/CANB 616        Gen. Inst/R3 Club     CANB 610    



CELL/CANB 616 Syllabus

Week Day Date Topic Lecturer Documents
1 M April 2 Mutagenic Mechanisms Mitch Turker
W April 4 Chemical Carcinogenesis/DNA Repair Stephen Lloyd
Th April 5 Cancer Stem Cells Missy Wong
2 M April 9 Tumor Microenvironment Lisa Coussens
W April 11 Metastasis & Angiogenesis Rosalie Sears
TH April 12 Imagining in Cancer Charles Springer
3 M April 16 Mutational Analysis of Solid Tumors - Sequenome Chris Coreless
W April 18 Predictive Gene Signatures Paul Spellman
Th April 19 Solid Cancer Path Megan Troxel
4 M April 23 Targeted Cancer Therapies Charles Lopez
W April 25 Immunotherapy Bernie Fox
Th April 26 Novel Mech. of Drug Delivery Wassana Yantasee
5 M April 30 Lung Alan Sadler
W May 2 Radiation Oncology Charles Thomas
Th May 3 Kidney George Thomas
6 M May 7 Head and Neck Neil Gross NOTE TIME AND ROOM: 10am RJH 5524
W May 9 Breast Steve Chui NOTE TIME AND ROOM: 10am RJH 5524
Th May 10 RESEARCH WEEK No class
7 M May 14 Ovarian Tanja Pejovic
W May 16 Prostate Joshi Alumkal
Th May 17 Skin Justin Leitenberger
8 M May 21 GI Charles Lopez
W May 23 Pancreas Gina Vacarro
Th May 24 Clinical Hem. Malignancy W. Harv. Fleming
9 M May 28 MEMORIAL DAY No Class
W May 30 Basic Science Hem Malignancy Jeff Tyner
Th May 31 Nutrition and Cancer Jackie Shannon
10 M June 4 Liver Scott Naugler
W June 6 Brain Cancer - Adult Edward Neuwelt
Th June 7 Tumor Board I Sears/Wong
11 M June 11 Brain Cancer - pediatric Kellie Nazemi
W June 13 Tumor Board II Sears/Wong
Th June 14 Pediatric Cancers Charles Keller

CELL616/CANB616 Advanced Topics in Cancer Biology Expectations Spring 2012

Goals of the course This upper level course will provide clinical insight into the clinical course, pathology, treatment, and therapeutic challenges that exist in a number of different organ-specific cancers. These clinical hallmarks and challenges are the important foundation on which novel basic science cancer research is built.

The course is designed to explore cancer mechanisms, hallmarks and novel technical approaches to unraveling underlying cancer behavior and characteristics, as well as organ-specific challenges, including current state of clinical diagnoses, treatment, prognosis and development of novel therapies. These lectures are designed to address the state of the art and to provide insight into the future of the field.

A critical aspect of the course is to provide the opportunity to basic science researchers to interact with clinical faculty. This will be accomplished through in class lectures, attendance at tumor-board, and shadowing with a clinical oncologist. We believe that this experience provides the opportunity to begin to understand the clinical challenges that can ultimately guide important discoveries in basic cancer research.


Grading policy

Your grade will be based upon three criteria:

1. Class participation (30%) How interactive you are during the lecture

2. Your tumor board presentation (30%)

3. Final Exam (40%) This exam is a written 2 page review of one cancer type (your choice).

Within this review you will include information addressing: background on this type of cancer, demographics, current therapies, known molecular mechanisms, molecular and animal models that exist, cutting edge research being performed to elucidate the underlying molecular pathway and/or development of novel therapeutics.

Personal tools